Role of ELMO1 in inflammation and cancer—clinical implications Stefania TocciStella-Rita IbeawuchiIbrahim M. Sayed Review 06 June 2022 Pages: 505 - 525
Glioblastoma, from disease understanding towards optimal cell-based in vitro models Chiara BoccellatoMarkus Rehm Review Open access 28 June 2022 Pages: 527 - 541
Application of circulating tumour cells to predict response to treatment in head and neck cancer Xi ZhangChameera Ekanayake WeeramangeChamindie Punyadeera Original Article Open access 23 June 2022 Pages: 543 - 555
Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry Ronghan ZhangXiaogang ChenQiang Hou Original Article 18 June 2022 Pages: 557 - 572
Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer Wang ChaominNiu WenhaoLi Yueguo Original Article 18 June 2022 Pages: 573 - 589
Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer B. B. M. SuelmannA. RademakerC. B. Moelans Original Article Open access 06 July 2022 Pages: 591 - 600
The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma Wenying ShuXue ZhuFanfan Zhou Original Article Open access 04 July 2022 Pages: 601 - 619
EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response Chan-Keng YangHung-Chih HsuHsuan Liu Original Article Open access 18 July 2022 Pages: 621 - 638
Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models Shulin LiSanne J. M. HoefnagelMembers of the Esophageal Adenocarcinoma Study Group Europe (EACSGE) Original Article Open access 28 July 2022 Pages: 639 - 658
AKT inhibition sensitizes EVI1 expressing colon cancer cells to irinotecan therapy by regulating the Akt/mTOR axis PradeepaVoddu SureshSoumen Chakraborty Original Article 14 July 2022 Pages: 659 - 675
VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas Jiale ZhouJunyun WangWei Xue Original Article Open access 14 July 2022 Pages: 677 - 687
Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway Huijie MiaoYajun GengYingbin Liu Original Article 23 July 2022 Pages: 689 - 708